tiprankstipranks
Advertisement
Advertisement

HALO Stock Latest News

Halozyme Earnings Call Highlights Surging Royalties, Raised Outlook
Company AnnouncementsHalozyme Earnings Call Highlights Surging Royalties, Raised Outlook
38s ago
HALO
Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged
PremiumRatings
Halozyme Buy Rating Reiterated as VYVGART Hytrulo Data Support Royalty Growth; $115 Price Target Unchanged
7h ago
HALO
Halozyme price target raised to $95 from $75 at Wells Fargo
PremiumThe Fly
Halozyme price target raised to $95 from $75 at Wells Fargo
8d ago
HALO
Halozyme price target raised to $105 from $93 at Morgan Stanley
PremiumThe Fly
Halozyme price target raised to $105 from $93 at Morgan Stanley
10d ago
HALO
Halozyme price target raised to $105 from $96 at TD Cowen
PremiumThe Fly
Halozyme price target raised to $105 from $96 at TD Cowen
10d ago
HALO
Halozyme price target raised to $95 from $75 at Wells Fargo
PremiumThe FlyHalozyme price target raised to $95 from $75 at Wells Fargo
11d ago
HALO
Leerink upgraded Halozyme to Outperform on growth, market leadership
Premium
The Fly
Leerink upgraded Halozyme to Outperform on growth, market leadership
11d ago
HALO
Halozyme upgraded to Outperform from Market Perform at Leerink
Premium
The Fly
Halozyme upgraded to Outperform from Market Perform at Leerink
11d ago
HALO
Halozyme price target raised to $93 from $92 at Citizens
PremiumThe Fly
Halozyme price target raised to $93 from $92 at Citizens
11d ago
HALO
Halozyme price target raised to $115 from $95 at H.C. Wainwright
PremiumThe Fly
Halozyme price target raised to $115 from $95 at H.C. Wainwright
11d ago
HALO
Halozyme reports Q2 non-GAAP EPS $2.28, consensus $1.82
PremiumThe Fly
Halozyme reports Q2 non-GAAP EPS $2.28, consensus $1.82
11d ago
HALO
Halozyme raises 2026 non-GAAP EPS view to $8.65-$9.00 from $7.75 to $8.25
PremiumThe Fly
Halozyme raises 2026 non-GAAP EPS view to $8.65-$9.00 from $7.75 to $8.25
11d ago
HALO
Is HALO a Buy, Before Earnings?
PremiumPre-EarningsIs HALO a Buy, Before Earnings?
14d ago
HALO
Halozyme announces global collaboration, license agreement with Incyte
Premium
The Fly
Halozyme announces global collaboration, license agreement with Incyte
29d ago
HALO
INCY
Halozyme announces key executive leadership transition and reorganization
Premium
Company Announcements
Halozyme announces key executive leadership transition and reorganization
2M ago
8K
HALO
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
PremiumThe Fly
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
2M ago
HALO
LFMD
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
PremiumRatings
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
2M ago
HALO
Halozyme Earnings Call Highlights Royalty-Fueled Growth
PremiumCompany Announcements
Halozyme Earnings Call Highlights Royalty-Fueled Growth
3M ago
HALO
Halozyme price target lowered to $93 from $96 at Morgan Stanley
PremiumThe Fly
Halozyme price target lowered to $93 from $96 at Morgan Stanley
3M ago
HALO
Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
PremiumRatingsHalozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
3M ago
HALO
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
Premium
Ratings
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
3M ago
HALO
Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52
Premium
The Fly
Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52
3M ago
HALO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >